Overview
Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects
Status:
Completed
Completed
Trial end date:
2017-01-01
2017-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of a single dose of PF-06835919 in healthy adult subjects.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:- Healthy males and female of non-childbearing potential;
- Body Mass Index 21.5 to 30.5 kg/m2 (inclusive);
- Total body weight >50 kg (110 lbs).
Exclusion Criteria:
-Evidence or history of clinically significant hematological, renal, endocrine, pulmonary,
gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease
(including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the
time of dosing).